New combo approach targets insomnia in veterans with PTSD

NCT ID NCT03937713

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 41 times

Summary

This study tested whether adding the sleep medication eszopiclone (Lunesta) to brief behavioral therapy improves sleep quality and CPAP use in veterans with PTSD and complex insomnia. Fifty-three veterans who had trouble sticking with CPAP therapy for sleep apnea took part. The goal was to see if the combination helps them sleep better and manage PTSD symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • VA Western New York Healthcare System, Buffalo, NY

    Buffalo, New York, 14215-1129, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eszopiclone (Lunesta)

What this could lead to

If successful, this could point toward a better way to improve sleep and CPAP use in veterans with PTSD and insomnia.

What could go wrong

This is a small, completed Phase 4 trial with only 53 participants, so results may not apply broadly. The drug eszopiclone can cause side effects like drowsiness or dizziness.

Conditions

The condition(s) this trial relates to.

insomnia obstructive sleep apnea syndrome post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.